Aquinnah Pharmaceuticals

Aquinnah Pharmaceuticals is leveraging the power of stress granule biology to develop oral small molecule drug candidates aimed at preventing TDP-43 pathology in amyotrophic lateral sclerosis (ALS), as well as other programs targeting Alzheimer’s disease through the development of tau stress granule pathology inhibitors.